RxDoctor Payments Data

Audrey Jones

Family Medicine · Alamo, TXNPI 1699956748

Payments from drug & device makers

$1,000,031in general payments, 2019–2025

Across 291 payments — averaging $3436.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$271K
  • Astrazeneca UK Limited$212K
  • Eisai Inc.$125K
  • Bayer$121K
  • Novartis$110K
  • GSK$80K
  • plus $81K from 9 others
$45,271in research payments, 2019–2025

Across 9 payments — averaging $5030.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$45K
  • Lucid Diagnostics Inc.$500

What the payments were for

  • Food & beverage$296100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer71$271,038
Astrazeneca UK Limited6$212,254
Eisai Inc.18$125,011
Bayer71$120,880
Novartis7$109,515
GSK33$80,452
Akebia Therapeutics Inc55$43,669
AbbVie(2 entities)14$17,271
Biohaven Pharmaceutical Holding Company Ltd.3$11,740
AstraZeneca4$6,279
Ionis Pharmaceuticals, Inc.4$975
Shionogi Inc1$775
Novo Nordisk1$113
Medline Industries LP1$31
Abbott2$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,000,031 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide27$45,535
EliquisApixaban15$22,314
FarxigaDapagliflozin Propanediol29$22,000
JardianceEmpagliflozin16$19,291
MounjaroTirzepatide12$17,463
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$4,540
Wixela InhubFluticasone Propion/Salmeterol13$3,782
Albuterol Sulfate HfaAlbuterol Sulfate39$1,720
Rosuvastatin Calcium176$1,651
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,248
Levothyroxine Sodium144$1,243
Hydroxychloroquine Sulfate16$1,196
Gabapentin40$1,177
Fentanyl13$1,168
Losartan Potassium99$1,165

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$113$45,53527 claims
PfizerEliquis$271,038$22,31415 claims
AstraZenecaFarxiga$6,279$22,00029 claims
AbbVieSynthroid$17,271$53818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Alamo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →